## Dawn E Sugarman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6410441/publications.pdf

Version: 2024-02-01

23 papers 1,005 citations

687363 13 h-index 677142 22 g-index

24 all docs 24 docs citations

times ranked

24

1366 citing authors

#	Article	IF	CITATIONS
1	Women's and men's experiences in group therapy for substance use disorders: A qualitative analysis. American Journal on Addictions, 2022, 31, 9-21.	1.4	5
2	Alcohol and COVID-19: How Do We Respond to This Growing Public Health Crisis?. Journal of General Internal Medicine, 2021, 36, 214-215.	2.6	25
3	Telemedicine for treating mental health and substance use disorders: reflections since the pandemic. Neuropsychopharmacology, 2021, 46, 1068-1070.	5.4	39
4	Clinicians' Perceptions of Rapid Scale-up of Telehealth Services in Outpatient Mental Health Treatment. Telemedicine Journal and E-Health, 2021, 27, 1399-1408.	2.8	36
5	Response to Letter to Editor from Drs. Barrett and Apodaca. Journal of General Internal Medicine, 2021, 36, 2477-2477.	2.6	O
6	Exploring Technology-Based Enhancements to Inpatient and Residential Treatment for Young Adult Women with Co-Occurring Substance Use. Journal of Dual Diagnosis, 2021, 17, 236-247.	1.2	5
7	Patients' perceptions of telehealth services for outpatient treatment of substance use disorders during the COVIDâ€19 pandemic. American Journal on Addictions, 2021, 30, 445-452.	1.4	36
8	Gender differences in the prevalence of heroin and opioid analgesic misuse in the United States, 2015–2019. Drug and Alcohol Dependence, 2021, 227, 108978.	3.2	13
9	Feasibility and Acceptability of a Web-Based, Gender-Specific Intervention for Women with Substance Use Disorders. Journal of Women's Health, 2020, 29, 636-646.	3.3	14
10	The relationship between perceived stress and depression in substance use disorder treatment. Drug and Alcohol Dependence, 2020, 207, 107819.	3.2	21
11	The Women's Recovery Group for Individuals with Co-Occurring Substance Use and Eating Disorders: Feasibility and Satisfaction in a Residential Eating Disorders Program. Alcoholism Treatment Quarterly, 2020, 38, 446-456.	0.8	4
12	Feasibility and Acceptability of a Gender-Specific Group Treatment for Men with Substance Use Disorders. Alcoholism Treatment Quarterly, 2019, 37, 422-441.	0.8	2
13	Feasibility and effects of galantamine on cognition in humans with cannabis use disorder. Pharmacology Biochemistry and Behavior, 2019, 181, 86-92.	2.9	10
14	Sex and gender differences in substance use disorders. Clinical Psychology Review, 2018, 66, 12-23.	11.4	566
15	Group therapy for women with substance use disorders: In-session affiliation predicts women's substance use treatment outcomes. Journal of Substance Abuse Treatment, 2018, 94, 60-68.	2.8	17
16	Technology-Based Interventions for Substance Use and Comorbid Disorders: An Examination of the Emerging Literature. Harvard Review of Psychiatry, 2017, 25, 123-134.	2.1	30
17	Treatment Outcomes for Women with Substance Use Disorders: a Critical Review of the Literature (2010–2016). Current Addiction Reports, 2017, 4, 482-502.	3.4	5
18	Measuring affiliation in group therapy for substance use disorders in the Women's Recovery Group study: Does it matter whether the group is all-women or mixed-gender?. American Journal on Addictions, 2016, 25, 573-580.	1.4	27

#	Article	IF	CITATIONS
19	Gender-based Outcomes and Acceptability of a Computer-assisted Psychosocial Intervention for Substance Use Disorders. Journal of Substance Abuse Treatment, 2015, 53, 9-15.	2.8	16
20	Predictors of drinking and functional outcomes for men and women following inpatient alcohol treatment. American Journal on Addictions, 2014, 23, 226-233.	1.4	20
21	Group therapy for women with substance use disorders: Results from the Women's Recovery Group Study. Drug and Alcohol Dependence, 2014, 142, 245-253.	3.2	47
22	Readability of Self-Report Alcohol Misuse Measures. Journal of Studies on Alcohol and Drugs, 2014, 75, 328-334.	1.0	10
23	Cognitive function as an emerging treatment target for marijuana addiction Experimental and Clinical Psychopharmacology, 2010, 18, 109-119.	1.8	57